Pantoprazole Sodium API

Name	Pantoprazole Sodium
Chinese name	泮托拉唑钠
Cas Number	138786-67-1
Source	Switzerland
Qualifications	USDMF/-/-/-/-

Pantoprazole Sodium was developed by Necomim, Germany. It is a new generation of proton pump inhibitor (PPI) after omeprazole and lansoprazole, and is a first-line treatment for peptic ulcer disease. This product inhibits the final step of gastric acid production by covalently binding with two sites of the H+-K+-ATPase system of gastric parietal cells. This effect is dose-dependent and inhibits gastric acid secretion in both basic and stimulated states. Compared with omeprazole and lansoprazole, pantoprazole sodium has a strong acid suppression ability. When used in combination with other drugs, it has the advantage of small drug interactions; the metabolic pathway of pantoprazole sodium can pass through The II enzyme system is carried out, so that the competitive action of the drug metabolism enzyme system is not easy to occur, and the interaction between drugs in the body is reduced. In 2018, China's public medical institutions had sales of peptic ulcer drugs at nearly 40 billion yuan, an increase of 2.33% year-on-year, and sales of pantoprazole sodium for injection were 7.913 billion yuan, occupying the leading position in the competitive landscape of digestive system and metabolic drugs status.

Hot Tags: pantoprazole sodium api, China, suppliers, manufacturers, factory, customized, price, pricelist, in stock, Dapoxetine API, Teriflunomide API, Aprepitant Aprepitant API, Bosentan API, Celecoxib API, Valganciclovir Hydrochloride API

• Previous: Sodium Bicarbonate API
• Next: Metoprolol Succinate API